Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections

G. Carmignani, A. F. De Rose, L. Olivieri, E. Salvatori, M. T. Rosignoli, P. Dionisio

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Introduction: The present study was performed to evaluate the efficacy and safety of a 10-day regimen of prulifloxacin 600 mg once daily as compared to ciprofloxacin 500 mg twice daily in the treatment of patients with complicated urinary tract infections (UTIs). Materials and Methods: 257 patients (mean age ± SD 62.3 ± 16.5) were enrolled and orally treated with prulifloxacin (127 patients) or ciprofloxacin (130 patients). The study was designed as a randomized, double-blind, double-dummy, controlled clinical trial. The primary efficacy parameter was the eradication of infecting strains (3 cfu/ml). The clinical outcome and tolerability were also assessed. Results: At baseline, the most common infecting strains were Escherichia coli (62.8%), Proteus mirabilis (7.1%) and Klebsiella pneumoniae (4.1%). At the early follow-up, the rate of patients showing successful treatment was 90.8% in the prulifloxacin group, and 77.8% in the ciprofloxacin group (p = 0.008). A positive clinical outcome was observed in 94.8 and 93.3% of prulifloxacin-and ciprofloxacin-treated patients. Both drugs were well tolerated. Two patients dropped out for treatment-related adverse events. Conclusions: The high urinary concentrations of prulifloxacin, combined with a broad-spectrum antimicrobial activity, allow its use in the empiric therapy of UTIs.

Original languageEnglish
Pages (from-to)326-331
Number of pages6
JournalUrologia Internationalis
Volume74
Issue number4
DOIs
Publication statusPublished - May 2005

Fingerprint

Ciprofloxacin
Urinary Tract Infections
Therapeutics
Proteus mirabilis
Controlled Clinical Trials
Klebsiella pneumoniae
prulifloxacin
Escherichia coli
Safety
Pharmaceutical Preparations

Keywords

  • Ciprofloxacin
  • Complicated UTI
  • Prulifloxacin

ASJC Scopus subject areas

  • Urology

Cite this

Carmignani, G., De Rose, A. F., Olivieri, L., Salvatori, E., Rosignoli, M. T., & Dionisio, P. (2005). Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urologia Internationalis, 74(4), 326-331. https://doi.org/10.1159/000084432

Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. / Carmignani, G.; De Rose, A. F.; Olivieri, L.; Salvatori, E.; Rosignoli, M. T.; Dionisio, P.

In: Urologia Internationalis, Vol. 74, No. 4, 05.2005, p. 326-331.

Research output: Contribution to journalArticle

Carmignani, G, De Rose, AF, Olivieri, L, Salvatori, E, Rosignoli, MT & Dionisio, P 2005, 'Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections', Urologia Internationalis, vol. 74, no. 4, pp. 326-331. https://doi.org/10.1159/000084432
Carmignani, G. ; De Rose, A. F. ; Olivieri, L. ; Salvatori, E. ; Rosignoli, M. T. ; Dionisio, P. / Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. In: Urologia Internationalis. 2005 ; Vol. 74, No. 4. pp. 326-331.
@article{aa24939300a0419dbc06793ecc175356,
title = "Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections",
abstract = "Introduction: The present study was performed to evaluate the efficacy and safety of a 10-day regimen of prulifloxacin 600 mg once daily as compared to ciprofloxacin 500 mg twice daily in the treatment of patients with complicated urinary tract infections (UTIs). Materials and Methods: 257 patients (mean age ± SD 62.3 ± 16.5) were enrolled and orally treated with prulifloxacin (127 patients) or ciprofloxacin (130 patients). The study was designed as a randomized, double-blind, double-dummy, controlled clinical trial. The primary efficacy parameter was the eradication of infecting strains (3 cfu/ml). The clinical outcome and tolerability were also assessed. Results: At baseline, the most common infecting strains were Escherichia coli (62.8{\%}), Proteus mirabilis (7.1{\%}) and Klebsiella pneumoniae (4.1{\%}). At the early follow-up, the rate of patients showing successful treatment was 90.8{\%} in the prulifloxacin group, and 77.8{\%} in the ciprofloxacin group (p = 0.008). A positive clinical outcome was observed in 94.8 and 93.3{\%} of prulifloxacin-and ciprofloxacin-treated patients. Both drugs were well tolerated. Two patients dropped out for treatment-related adverse events. Conclusions: The high urinary concentrations of prulifloxacin, combined with a broad-spectrum antimicrobial activity, allow its use in the empiric therapy of UTIs.",
keywords = "Ciprofloxacin, Complicated UTI, Prulifloxacin",
author = "G. Carmignani and {De Rose}, {A. F.} and L. Olivieri and E. Salvatori and Rosignoli, {M. T.} and P. Dionisio",
year = "2005",
month = "5",
doi = "10.1159/000084432",
language = "English",
volume = "74",
pages = "326--331",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections

AU - Carmignani, G.

AU - De Rose, A. F.

AU - Olivieri, L.

AU - Salvatori, E.

AU - Rosignoli, M. T.

AU - Dionisio, P.

PY - 2005/5

Y1 - 2005/5

N2 - Introduction: The present study was performed to evaluate the efficacy and safety of a 10-day regimen of prulifloxacin 600 mg once daily as compared to ciprofloxacin 500 mg twice daily in the treatment of patients with complicated urinary tract infections (UTIs). Materials and Methods: 257 patients (mean age ± SD 62.3 ± 16.5) were enrolled and orally treated with prulifloxacin (127 patients) or ciprofloxacin (130 patients). The study was designed as a randomized, double-blind, double-dummy, controlled clinical trial. The primary efficacy parameter was the eradication of infecting strains (3 cfu/ml). The clinical outcome and tolerability were also assessed. Results: At baseline, the most common infecting strains were Escherichia coli (62.8%), Proteus mirabilis (7.1%) and Klebsiella pneumoniae (4.1%). At the early follow-up, the rate of patients showing successful treatment was 90.8% in the prulifloxacin group, and 77.8% in the ciprofloxacin group (p = 0.008). A positive clinical outcome was observed in 94.8 and 93.3% of prulifloxacin-and ciprofloxacin-treated patients. Both drugs were well tolerated. Two patients dropped out for treatment-related adverse events. Conclusions: The high urinary concentrations of prulifloxacin, combined with a broad-spectrum antimicrobial activity, allow its use in the empiric therapy of UTIs.

AB - Introduction: The present study was performed to evaluate the efficacy and safety of a 10-day regimen of prulifloxacin 600 mg once daily as compared to ciprofloxacin 500 mg twice daily in the treatment of patients with complicated urinary tract infections (UTIs). Materials and Methods: 257 patients (mean age ± SD 62.3 ± 16.5) were enrolled and orally treated with prulifloxacin (127 patients) or ciprofloxacin (130 patients). The study was designed as a randomized, double-blind, double-dummy, controlled clinical trial. The primary efficacy parameter was the eradication of infecting strains (3 cfu/ml). The clinical outcome and tolerability were also assessed. Results: At baseline, the most common infecting strains were Escherichia coli (62.8%), Proteus mirabilis (7.1%) and Klebsiella pneumoniae (4.1%). At the early follow-up, the rate of patients showing successful treatment was 90.8% in the prulifloxacin group, and 77.8% in the ciprofloxacin group (p = 0.008). A positive clinical outcome was observed in 94.8 and 93.3% of prulifloxacin-and ciprofloxacin-treated patients. Both drugs were well tolerated. Two patients dropped out for treatment-related adverse events. Conclusions: The high urinary concentrations of prulifloxacin, combined with a broad-spectrum antimicrobial activity, allow its use in the empiric therapy of UTIs.

KW - Ciprofloxacin

KW - Complicated UTI

KW - Prulifloxacin

UR - http://www.scopus.com/inward/record.url?scp=20844438699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844438699&partnerID=8YFLogxK

U2 - 10.1159/000084432

DO - 10.1159/000084432

M3 - Article

C2 - 15897698

AN - SCOPUS:20844438699

VL - 74

SP - 326

EP - 331

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 4

ER -